Association of Pseudomonas aeruginosa infection stage with lung function trajectory in children with cystic fibrosis
Copyright © 2023. Published by Elsevier B.V..
BACKGROUND: Pseudomonas aeruginosa (Pa) infection in cystic fibrosis (CF) is characterized in stages: never (prior to first positive culture) to incident (first positive culture) to chronic. The association of Pa infection stage with lung function trajectory is poorly understood and the impact of age on this association has not been examined. We hypothesized that FEV1 decline would be slowest prior to Pa infection, intermediate after incident infection and greatest after chronic Pa infection.
METHODS: Participants in a large US prospective cohort study diagnosed with CF prior to age 3 contributed data through the U.S. CF Patient Registry. Cubic spline linear mixed effects models were used to evaluate the longitudinal association of Pa stage (never, incident, chronic using 4 different definitions) with FEV1 adjusted for relevant covariates. Models contained interaction terms between age and Pa stage.
RESULTS: 1,264 subjects born 1992-2006 provided a median 9.5 (IQR 0.25 to 15.75) years of follow up through 2017. 89% developed incident Pa; 39-58% developed chronic Pa depending on the definition. Compared to never Pa, incident Pa infection was associated with greater annual FEV1 decline and chronic Pa infection with the greatest FEV1 decline. The most rapid FEV1 decline and strongest association with Pa infection stage was seen in early adolescence (ages 12-15).
CONCLUSIONS: Annual FEV1 decline worsens significantly with each Pa infection stage in children with CF. Our findings suggest that measures to prevent chronic infection, particularly during the high-risk period of early adolescence, could mitigate FEV1 decline and improve survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 22(2023), 5 vom: 17. Sept., Seite 857-863 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rosenfeld, Margaret [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cystic fibrosis |
|---|
| Anmerkungen: |
Date Completed 28.11.2023 Date Revised 24.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcf.2023.05.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357198468 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357198468 | ||
| 003 | DE-627 | ||
| 005 | 20240424231830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcf.2023.05.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1385.xml |
| 035 | |a (DE-627)NLM357198468 | ||
| 035 | |a (NLM)37217389 | ||
| 035 | |a (PII)S1569-1993(23)00134-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rosenfeld, Margaret |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of Pseudomonas aeruginosa infection stage with lung function trajectory in children with cystic fibrosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.11.2023 | ||
| 500 | |a Date Revised 24.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: Pseudomonas aeruginosa (Pa) infection in cystic fibrosis (CF) is characterized in stages: never (prior to first positive culture) to incident (first positive culture) to chronic. The association of Pa infection stage with lung function trajectory is poorly understood and the impact of age on this association has not been examined. We hypothesized that FEV1 decline would be slowest prior to Pa infection, intermediate after incident infection and greatest after chronic Pa infection | ||
| 520 | |a METHODS: Participants in a large US prospective cohort study diagnosed with CF prior to age 3 contributed data through the U.S. CF Patient Registry. Cubic spline linear mixed effects models were used to evaluate the longitudinal association of Pa stage (never, incident, chronic using 4 different definitions) with FEV1 adjusted for relevant covariates. Models contained interaction terms between age and Pa stage | ||
| 520 | |a RESULTS: 1,264 subjects born 1992-2006 provided a median 9.5 (IQR 0.25 to 15.75) years of follow up through 2017. 89% developed incident Pa; 39-58% developed chronic Pa depending on the definition. Compared to never Pa, incident Pa infection was associated with greater annual FEV1 decline and chronic Pa infection with the greatest FEV1 decline. The most rapid FEV1 decline and strongest association with Pa infection stage was seen in early adolescence (ages 12-15) | ||
| 520 | |a CONCLUSIONS: Annual FEV1 decline worsens significantly with each Pa infection stage in children with CF. Our findings suggest that measures to prevent chronic infection, particularly during the high-risk period of early adolescence, could mitigate FEV1 decline and improve survival | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cystic fibrosis | |
| 650 | 4 | |a Lung function | |
| 650 | 4 | |a Pseudomonas aeruginosa | |
| 700 | 1 | |a Faino, Anna V |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Pingping |e verfasserin |4 aut | |
| 700 | 1 | |a Onchiri, Frankline M |e verfasserin |4 aut | |
| 700 | 1 | |a Blue, Elizabeth E |e verfasserin |4 aut | |
| 700 | 1 | |a Collaco, Joseph M |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, William W |e verfasserin |4 aut | |
| 700 | 1 | |a Szczesniak, Rhonda |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yi-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Bamshad, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Gibson, Ronald L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society |d 2002 |g 22(2023), 5 vom: 17. Sept., Seite 857-863 |w (DE-627)NLM15136754X |x 1873-5010 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:5 |g day:17 |g month:09 |g pages:857-863 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcf.2023.05.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 5 |b 17 |c 09 |h 857-863 | ||